InvestorsHub Logo

F1ash

07/18/17 6:41 PM

#111662 RE: nidan7500 #111661

...when no molecule has EVER done what A2-73 has done.



Boy that sounds really exciting. What exactly did A2-73 do that has never been done before?

Amatuer17

07/18/17 8:29 PM

#111672 RE: nidan7500 #111661

See this ALZ product and trials - co completed P1, double blind placebo controlled P2b for 399 patients with very good results and completed enrollment of 800 patients for P3 study for ALZ - it is a non-plaque approach. It seems way better than AVXL

http://vtvtherapeutics.com/pipeline/azeliragon

So why AVXL is so special and it has done that will force FDA to allow them to exclude P2b - dose optimization and large P3 study?

What you have is 32 patient - 7 dropped - non-conclusive study.

jimmy667

07/18/17 10:44 PM

#111694 RE: nidan7500 #111661

Good perspective. Well spoken.